MedTrace Logo

Comparing Everolimus and Sirolimus in Renal Transplant Recipients

NCT01976390 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-10-21

Study results available
· View outcomes & findings →

Summary

This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).

Conditions

  • Renal Failure

Interventions

DRUG

Everolimus

0.75mg twice a day, Orally, starting on day of transplant

DRUG

Sirolimus

5mg, Orally, starting on day of transplant; decreasing to 3mg

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Ohio State University

    lead OTHER

Principal Investigators

  • Amer Rajab, MD · OSU Wexner Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-01
Primary Completion
2018-07-11
Completion
2019-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01976390 on ClinicalTrials.gov